当前位置：
X-MOL 学术
›
J. Natl. Cancer Inst.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Overall Survival Prediction and Usefulness of Second-Line Chemotherapy in Advanced Pancreatic Adenocarcinoma
Journal of the National Cancer Institute ( IF 9.9 ) Pub Date : 2017-04-04 , DOI: 10.1093/jnci/djx037 Angélique Vienot , Guillaume Beinse , Christophe Louvet , Louis de Mestier , Aurélia Meurisse , Francine Fein , Bruno Heyd , Denis Cleau , Christelle d’Engremont , Anne-Claire Dupont-Gossart , Zaher Lakkis , Christophe Tournigand , Olivier Bouché , Benoît Rousseau , Cindy Neuzillet , Franck Bonnetain , Christophe Borg , Dewi Vernerey
Journal of the National Cancer Institute ( IF 9.9 ) Pub Date : 2017-04-04 , DOI: 10.1093/jnci/djx037 Angélique Vienot , Guillaume Beinse , Christophe Louvet , Louis de Mestier , Aurélia Meurisse , Francine Fein , Bruno Heyd , Denis Cleau , Christelle d’Engremont , Anne-Claire Dupont-Gossart , Zaher Lakkis , Christophe Tournigand , Olivier Bouché , Benoît Rousseau , Cindy Neuzillet , Franck Bonnetain , Christophe Borg , Dewi Vernerey
Background: In advanced pancreatic ductal adenocarcinoma (aPDAC), there is no consensual strategy for second-line chemotherapy (L2). Better discrimination of overall survival (OS) may help clinical decision-making. We aimed to predict OS from the beginning of L2 and to assess the benefit from chemotherapy among the identified risk groups.
中文翻译：
晚期胰腺腺癌的总生存预测和二线化疗的实用性。
背景：在晚期胰腺导管腺癌（aPDAC）中，尚无共识的二线化疗策略（L2）。更好地区分总体生存率（OS）可能有助于临床决策。我们的目标是从L2开始就预测OS，并评估已确定风险组中化疗的益处。
更新日期：2017-09-06
中文翻译：
晚期胰腺腺癌的总生存预测和二线化疗的实用性。
背景：在晚期胰腺导管腺癌（aPDAC）中，尚无共识的二线化疗策略（L2）。更好地区分总体生存率（OS）可能有助于临床决策。我们的目标是从L2开始就预测OS，并评估已确定风险组中化疗的益处。
京公网安备 11010802027423号